Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly & Co.

www.lilly.com

Latest From Eli Lilly & Co.

DOJ's Investigation Of Reckitt's Suboxone Promotions Marks The Return Of The Big Settlement

$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.

Advertising, Marketing & Sales Legal Issues

FTC's First Product Hopping Complaint Targets Safety Claims For Suboxone Film Formulation

Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.

Legal Issues Enforcement

New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund

Two of the three companies vying for an additional share of England’s CDK4/6 inhibitor market have now secured reimbursement for the use of their products in combination with fulvestrant for advanced breast cancer.
Reimbursement United Kingdom

Capricor’s Interim Data Could Offer Hope For Older DMD Patients

Although only interim data from six treated patients, Capricor’s Phase II DMD study shows improvements in upper limb performance, grip strength and respiration. Cardiac performance shows positive trend, but not yet statistical significance.

Clinical Trials Rare Diseases
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register